Wednesday, October 31, 2012

Kyowa Hakko Kirin discontinues Phase 3 clinical study of ARQ194 (Tivantinib) in combination with Erlotinib in NSCLC

The trial has been discontinued based on the recommendation of safety committee. Earlier patient enrollment had been suspended because of higher frequency of observed interstital lung disease with the treatment. 
The  study discontinued (ATTENTION) was a randomized, double-blind trial comparing overall survival (OS) of patients treated with ARQ 197 and erlotinib to OS of patients treated with placebo and erlotinib. The target number of patients to be enrolled in this study was 460 in Japan, Taiwan and Korea

Enter your email address:


Delivered by FeedBurner